{"disease":{"id":"relapsed-or-refractory-plasma-cell-neoplasms","name":"relapsed or refractory plasma cell neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07519187","title":"CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"The General Hospital of Western Theater Command","has_results":false},{"nct_id":"NCT06986434","title":"CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Affiliated Hospital to Academy of Military Medical Sciences","has_results":false},{"nct_id":"NCT07077330","title":"CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}